{
  "nctId": "NCT04873245",
  "briefTitle": "Lifestyle Counseling and Medication for Adolescent Weight Management",
  "officialTitle": "Lifestyle Counseling and Medication for Adolescent Weight Management",
  "protocolDocument": {
    "nctId": "NCT04873245",
    "filename": "Prot_SAP_000.pdf",
    "label": "Study Protocol and Statistical Analysis Plan",
    "date": "2025-03-12",
    "uploadDate": "2025-05-08T10:03",
    "size": 1009121,
    "downloadUrl": "https://clinicaltrials.gov/api/v2/studies/NCT04873245/document/Prot_SAP_000.pdf",
    "hasProtocol": true,
    "hasSap": true,
    "hasIcf": false
  },
  "phase": [
    "PHASE2"
  ],
  "studyType": "INTERVENTIONAL",
  "allocation": "RANDOMIZED",
  "interventionModel": "PARALLEL",
  "masking": "NONE",
  "enrollmentInfo": {
    "enrollmentCount": 120,
    "enrollmentType": "ACTUAL"
  },
  "timeline": {
    "startDate": "2022-03-15",
    "completionDate": "2027-07-31",
    "primaryCompletionDate": "2026-07-31",
    "firstSubmitDate": "2021-04-30",
    "firstPostDate": "2021-05-05"
  },
  "eligibilityCriteria": {
    "criteria": "Inclusion Criteria:\n\n* Severe obesity (Body Mass Index (BMI) \\>/= 120% of the 95th percentile or BMI \\>/= 35 kg/m2)\n* Age 12 to \\< 18 years old and Tanner stage \\>1\n\nExclusion Criteria:\n\n* Diabetes (type 1 or 2)\n* Current or recent (\\< 6 months prior to enrollment) use of anti-obesity medication(s) defined as orlistat, phentermine, topiramate, combination phentermine/topiramate, liraglutide (or other GLP-1RA) and/or combination naltrexone/bupropion (monotherapy use of naltrexone or bupropion is not an exclusion)\n* Previous bariatric surgery\n* Any history of treatment with growth hormone\n* Medically-documented history of bulimia nervosa\n* Major psychiatric disorder as determined by the local medical monitor\n* Unstable depression requiring hospitalization within the previous 6 month\n* Any history of suicide attempt\n* History of suicidal ideation or self-harm within the previous 30 days\n* Current pregnancy or plans to become pregnant\n* ALT or AST \\>/= 5 times the upper limit of normal\n* Creatinine \\> 1.2 mg/dL\n* Uncontrolled hypertension as determined by the local medical monitor\n* Diagnosed and medically-documented monogenic obesity\n* Medically-documented history of cholelithiasis\n* Untreated thyroid disorder\n* Medically documented history of pancreatitis\n* Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2\n* Clinically significant heart disease as determined by the local medical monitor\n* Personal history of malignant neoplasms within the past five years\n* Hypersensitivity to any component of semaglutide",
    "healthyVolunteers": false,
    "sex": "ALL",
    "minimumAge": "12 Years",
    "maximumAge": "17 Years",
    "stdAges": [
      "CHILD"
    ]
  },
  "endpoints": {
    "primary": [
      {
        "measure": "Change in body mass index",
        "description": "The percent change in body mass index (BMI) from Baseline to Week 52 will be calculated. BMI is defined as a person's weight in kilograms divided by the square of height in meters.",
        "timeFrame": "52 weeks"
      }
    ],
    "secondary": [],
    "other": []
  },
  "complexityMetrics": {
    "eligibilityCriteria": {
      "inclusionCount": 1,
      "exclusionCount": 1,
      "totalCount": 2
    },
    "endpoints": {
      "primaryCount": 1,
      "secondaryCount": 0,
      "otherCount": 0,
      "totalCount": 1
    },
    "studyDesign": {
      "phases": [
        "PHASE2"
      ],
      "isRandomized": true,
      "isMasked": false,
      "interventionModel": "PARALLEL"
    },
    "overallComplexityScore": 24,
    "complexityCategory": "Simple"
  },
  "collectionDate": "2025-09-22T02:30:16.006Z",
  "dataSource": "ClinicalTrials.gov API v2 - Comprehensive Collection"
}